We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

MINDRAY In-Vitro Diagnostics

Mindray offers a range of chemistry and hematology analyzers, designed to meet the needs of smaller labs as a main in... read more Featured Products: More products

Download Mobile App

Mindray Hematology Analyzers Measure Increased Eosinophil Count Associated with Subprophylactic Anticoagulation in COVID-19 Patients

By LabMedica International staff writers
Posted on 26 Apr 2021
Print article
Image: Mindray BC- 6800 auto hematology analyzer (Photo courtesy of Mindray)
Image: Mindray BC- 6800 auto hematology analyzer (Photo courtesy of Mindray)
Mindray (Shenzhen, China) hematology analyzers are using advanced technologies to detect increased eosinophil count that is associated with the level of subprophylactic anticoagulation in COVID-19 patients.

Is prophylactic anticoagulant therapy a common treatment for clinicians to deal with thrombotic events in COVID-19? Is there a connection between the eosinophil count and anticoagulation monitoring in COVID-19 patients? Thrombosis has emerged as an important complication among hospitalized patients with COVID-19. A prothrombotic state induced by SARS-Cov-2 can manifest in venous thromboembolism (VTE), arterial thrombosis and disseminated intravenous coagulation (DIC). In 28 studies including 2928 patients, thrombotic complications occurred in 34% of ICU patients, deep venous thrombosis (DVT) reported in 16.1% and pulmonary embolism in 12.6% of patients, and were associated with high mortality.

Low molecular weight heparin (LMWH) and unfractionated heparin (UFH) are recommended by the international society for thrombosis on hemostasis (ISTH), American Society of Hematology (ASH) for the treatment of thrombotic events associated with SARS-CoV-2 infection. Particularly, LMWH has a stronger antithrombotic effect than UFH. LMWH predominantly acts on factor Xa. For this reason, LMWH activity is monitored using serum anti-factor Xa activity (AFXa) levels instead of activated Partial Thromboplastin Time (aPTT). Enoxaparin is one of the most important LMWH. The AFXa level reached peak 3-5 hours after administration. The AFXa levels below 0.2 IU/mL may increase the risk of VTE in COVID-19 patients, due to the hypercoagulability.

Dr. Selma Ari has found the increased eosinophil count is associated with the level of subprophylactic anticoagulation in COVID-19 patients. In the laboratory results, only eosinophil counts and AFXa are significantly different between subprophylactic anticoagulation group and prophylactic anticoagulation group when the patients are admitted to hospital. Laboratory analysis collected before the discharge of patients revealed that eosinophil counts in subprophylactic anticoagulation group were higher than in prophylactic anticoagulation group , whereas AFXa were lower in subprophylactic anticoagulation group. Eosinophil induces platelet aggregation and thrombus formation through the production of major basic protein (MBP) and eosinophil peroxidase (EPX). Enzymes released from eosinophils (peroxidases, cationic proteins, and neurotoxins) may decrease the anticoagulant activity of heparin.

In this study, in subprophylactic anticoagulation group, high eosinophil levels had lower anticoagulant activity in COVID-19 patients. Eosinophil counts were examined with Mindray BC- 6800 auto hematology analyzer. Its SF Cube analysis technology can produce three-dimensional scattergram which can help doctors better identify and differentiate blood cell populations, especially to reveal abnormal cell population undetected by other techniques. Nowadays a large number of parameters on BC-6800 can be used in clinical diagnosis and scientific research. Therefore, clinicians are welcome to do more research on COVID-19 on Mindray BC-6200/BC-6800/BC-6800Plus/ CAL 6000/CAL 8000.

Gold Supplier
SARS-CoV-2, Flu A/B, and RSV Test
COVID-19 IgM/IgA/IgG Test
Gold Supplier

Print article
Mayo Medical Laboratories
BIOHIT  Healthcare OY


Molecular Diagnostics

view channel
Image: Photograph of the novel capsule-based smell test (Photo courtesy of Queen Mary University of London)

A Novel Capsule-Based Smell Test for Diagnosis of Neurological and Respiratory Diseases

To aid in diagnosing diseases where loss of the sense of smell is a symptom, such as in chronic neurological conditions like Parkinson's and Alzheimer's diseases and in acute respiratory infections such... Read more


view channel
Image: The Hamamatsu Photonics Nanozoomer 1 Digital Slide Scanner (Photo courtesy of University of Adelaide)

Genetic Background and Clinicopathologic Features Established for Adult-Onset Nephronophthisis

Nephronophthisis (NPH) is a genetic disorder of the kidneys which mainly affects children. It is classified as a medullary cystic kidney disease. The disorder is inherited in an autosomal recessive fashion... Read more


view channel
Image: DxA 5000 Fit (Photo courtesy of Beckman Coulter)

Beckman Coulter Becomes First Diagnostics Company to Offer Workflow Automation Specifically for Mid-Volume Laboratories

Beckman Coulter (Brea, CA, USA) has announced the global launch of the DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.